Integrated BioPharma Reports Quarterly Results with Increased Revenue

Integrated BioPharma, Inc. (OTCQX:INBP) announced its financial outcomes for the quarter ending December 31, 2024. The company reported a revenue of $12.6 million, showing an increase from $11.5 million in 2023, marking a growth of 9.6%. Operating income was $0.2 million, a turnaround from the previous year's operating loss of $0.5 million.

Revenue for the six-month period also increased, reaching $26.2 million compared to $24.4 million in 2023, a 7.4% growth. Operating income for these six months was $0.7 million, contrasting with a $0.5 million loss in 2023. Net income for Q4 2024 was $0.1 million, while the company experienced a net loss in the same quarter of 2023.

The Co-CEOs, Riva Sheppard and Christina Kay, emphasized their focus on expanding the customer base and reported that major clients accounted for 82% and 90% of revenue in 2024 and 2023, respectively.